Streetbeat News

BAYRY

Bayer AG

https://www.bayer.de/

CEO

Werner Baumann

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

5.22

Mkt cap

20B

Volume

133K

High

5.22

P/E Ratio

-22.43

52-wk high

9.79

Low

5.14

Div yield

0.01

52-wk low

4.94

Bayer is advancing its Radiology portfolio with innovations in AI and new collaboration agreements, which will be showcased at the RSNA 2024 meeting.

Portfolio Pulse from

December 01, 2024 | 3:30 pm

The FDA has accepted Bayer's supplemental New Drug Application (sNDA) for expanding the label of Nubeqa, a prostate cancer treatment. This marks a significant step in Bayer's efforts to broaden the use of Nubeqa.

Portfolio Pulse from

November 22, 2024 | 8:00 pm

Bayer shareholders urge CEO Bill Anderson to accelerate turnaround efforts to improve efficiency and drug development, aiming to restore confidence and revive the company's share price, which has hit 20-year lows.

Portfolio Pulse from

November 15, 2024 | 6:15 am

Bayer's third-quarter earnings were below expectations due to impairment losses in the Crop Science division. However, the Pharmaceutical business showed strong performance, with sales boosted by Nubeqa and Kerendia.

Portfolio Pulse from

November 12, 2024 | 8:00 pm

Bayer's stock faces risks from litigation and poor M&As, but its low valuation suggests potential long-term upside, especially post-2025. Despite challenges and a dividend cut, Bayer's fundamentals are solid, with a potential 30% annual upside. Consumer Health shows promise, but Crop Science and Pharma face headwinds.

Portfolio Pulse from

November 12, 2024 | 1:45 pm

Bayer's stock is experiencing a significant decline, dropping 11% in German trading, following the company's announcement of a reduced full-year earnings target. The conglomerate also warned of potential lower profits next year due to challenges in the agricultural market.

Portfolio Pulse from

November 12, 2024 | 1:00 pm

Bayer's stock experienced a decline following a profit warning related to its crop-sciences unit, indicating challenges in agricultural demand.

Portfolio Pulse from

November 12, 2024 | 12:30 pm

Bayer has reduced its full-year operating earnings outlook due to weaker agricultural markets in Latin America.

Portfolio Pulse from

November 12, 2024 | 7:00 am

Bayer AG has submitted a marketing authorization application to the European Medicines Agency for its menopause drug elinzanetant, following positive Phase 3 trial results. The drug showed significant reduction in vasomotor symptoms and improved quality of life over 52 weeks.

Portfolio Pulse from Vandana Singh

October 15, 2024 | 1:26 pm

Bayer AG has submitted an application to the European Medicines Agency for the approval of darolutamide, an oral androgen receptor inhibitor, for use in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer. The application is based on positive Phase III ARANOTE trial results.

Portfolio Pulse from Vandana Singh

October 14, 2024 | 3:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.